Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $46.40 USD
Change Today +1.80 / 4.04%
Volume 785.4K
NUVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NUVA) Snapshot

Open
$44.99
Previous Close
$44.60
Day High
$46.56
Day Low
$44.65
52 Week High
01/8/15 - $51.23
52 Week Low
04/30/14 - $31.35
Market Cap
2.2B
Average Volume 10 Days
591.7K
EPS TTM
$0.42
Shares Outstanding
48.1M
EX-Date
--
P/E TM
111.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NUVA)

nuvasive inc (NUVA) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NUVA) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NUVA) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
President and Chief Operating Officer
Total Annual Compensation: $520.0K
President of US Sales and Services
Total Annual Compensation: $375.0K
Special Advisor To The Chief Executive Office...
Total Annual Compensation: $550.0K
Compensation as of Fiscal Year 2013.

nuvasive inc (NUVA) Key Developments

NuVasive Seeks Acquisitions

NuVasive, Inc. (NasdaqGS:NUVA) is looking for acquisitions. Quentin Blackford, Exexcutive Vise President and Chief financial Officer of NuVasive states, "At the same time we want to balance that with our appetite to be acquisitive. We want to play in the M&A space. There are opportunities to grow our international business and expand the scale of that business rapidly in some key markets. We want to look at those opportunities and ensure that we have the potential to do it."

NuVasive Announces Successful Appeal of Medtronic Verdict

NuVasive, Inc. announced that the Court of Appeals for the Federal Circuit overturned the damages award in the Company's ongoing patent lawsuit with Medtronic Sofamor Danek USA, Inc. and Warsaw Orthopedic, Inc. The appeal challenged a September 2011 jury verdict in the first phase of the litigation between NuVasive and Medtronic. The jury found that the three remaining patents at issue in the appeal were infringed awarding total monetary damages of $660,000 to NuVasive and approximately $102 million to Medtronic, which included lost profits, the sale of ancillary or 'convoyed' products and royalties. On March 2, 2015, the three Judge panel of the Court of Appeals issued a unanimous decision upholding the jury's finding of liability as to all patents, but overturning the damage award against NuVasive as improper. Significantly, the Court of Appeals held that the damages award was erroneous because Medtronic is not permitted to recover damages for lost profits or for the sale of convoyed products. Absent further proceedings on appeal, the case will be returned to the District Court for further proceedings to determine a proper damage award based solely on a reasonable royalty. The timing of a retrial to determine the new damages amount is difficult to predict, but could occur later in 2015.

NuVasive, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 10:30 AM

NuVasive, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 10:30 AM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUVA:US $46.40 USD +1.80

NUVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $50.97 USD +0.61
Globus Medical Inc $24.86 USD +0.28
Integra LifeSciences Holdings Corp $62.14 USD +1.64
Masimo Corp $32.76 USD +0.92
Thoratec Corp $42.11 USD +1.11
View Industry Companies
 

Industry Analysis

NUVA

Industry Average

Valuation NUVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.